Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
TGTX > SEC Filings for TGTX > Form 8-K on 11-Dec-2013All Recent SEC Filings

Show all filings for TG THERAPEUTICS, INC. | Request a Trial to NEW EDGAR Online Pro

Form 8-K for TG THERAPEUTICS, INC.


11-Dec-2013

Other Events, Financial Statements and Exhibits


Item 8.01. Other Events.

On December 9, 2013, TG Therapeutics, Inc. (the "Company") issued a press release announcing clinical results from an ongoing first-in-human Phase I single agent study of TGR-1202, the Company's oral PI3K-Delta inhibitor being developed for the treatment of select hematologic malignancies, presented at the American Society of Hematology Meeting in New Orleans, LA. A copy of the press release is being filed as Exhibit 99.1 and is incorporated herein by reference.



Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 Press release issued by the Company on December 9, 2013.

- 2 -

  Add TGTX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for TGTX - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.